Citations

Showing 10 of 108081 citations.

What Should We Expect for Real-World Outcomes of Deep Brain Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy?
Lundstrom, Brian N. , Gregg, Nicholas M. , Lundstrom, Brian Nils , Gregg, Nicholas M

Mayo Clinic

Neurology | March 20, 2023 | Volume: 100 | Issue: 18 | Pages: 845-846

10.1212/wnl.0000000000201455 | PMID 36941073 Get It

Annals for Hospitalists Inpatient Notes - Clinical Pearls—Outpatient Parenteral Antimicrobial Therapy for Infective Endocarditis in Persons Who Inject Drugs
Baddour, Larry M. , Baddour, Larry , DeSimone, Daniel C.

Mayo Clinic

Annals of Internal Medicine | March 20, 2023 | Volume: 176 | Issue: 3 | Pages: No page available

10.7326/m23-0241 | PMID 36940459 Get It

Acquiring the Diagnosis of an Acquired Tracheoesophageal Fistula with EtCO2: A Case Discussion with Review of the Literature
BORJA, JANINE BEATRICE , Patel, Ghanshyam , Baloch, Luqman , Aqeel, Ammar, Chand, Mool, Dawood, Altaf , Khan, Naser , Korsapati, Hariprasad, Korsapati, Hariprasad Reddy

Mayo Clinic

Case Reports in Gastrointestinal Medicine | March 20, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-3

10.1155/2023/9437558 | PMID 36992709 Get It

Acquired tracheoesophageal fistula (TEF) is a rare complication of esophageal or lung cancer. A 57-year-old male presented with complaints of vomiting, cough, 20 lb weight loss, and progressive dysphagia. Early laryngoscopy and CT chest showed a normal pharynx with an irregular thickness of the thoracic esophagus. The upper gastrointestinal endoscopy (UGIE) and upper endoscopic ultrasound (EUS) revealed a hypoechoic mass evolving as complete obstruction. During the procedure, minimal CO2 was used for insufflation; however, when attempts were made to traverse the obstruction, capnography revealed an end-tidal CO2 (EtCO2) estimating 90 mmHg indicating possible TEF. This case depicts the use of capnography during UGIE in diagnosing an acquired TEF.
USP10 Regulates ZEB1 Ubiquitination and Protein Stability to Inhibit ZEB1-Mediated Colorectal Cancer Metastasis
Sun, Lei , Yu, Jia , Guinney, Justin , Qin, Bo , Sinicrope, Frank A. , Sinicrope, Frank A

Mayo Clinic

Molecular Cancer Research | March 20, 2023 | Volume: 21 | Issue: 6 | Pages: 578-590

10.1158/1541-7786.mcr-22-0552 | PMID 36940483 Get It

Abstract Zinc finger E-box–binding homeobox 1 (ZEB1) is a transcription factor that can promote tumor invasion and metastasis by inducing epithelial-to-mesenchymal transition (EMT). To date, regulation of ZEB1 by RAS/RAF signaling remains unclear, and few studies have examined posttranslation modification of ZEB1, including its ubiquitination. In human colorectal cancer cell lines with RAS/RAF/MEK/ERK activation, an interaction of ZEB1 with the deubiquitinase ubiquitin-specific protease 10 (USP10) was identified whereby USP10 modifies ZEB1 ubiquitination and promotes its proteasomal degradation. Regulation of the USP10–ZEB1 interaction by MEK–ERK signaling was shown whereby constitutive activation of ERK can phosphorylate USP10 at Ser236 to impair its interaction with ZEB1 and enable ZEB1 protein stabilization. Stabilized ZEB1 was shown to promote colorectal cancer metastatic colonization in a mouse tail vein injection model. Conversely, MEK–ERK inhibition blocked USP10 phosphorylation and enhanced the USP10–ZEB1 interaction shown to suppress ZEB1-mediated tumor cell migration and metastasis. In conclusion, we demonstrate a novel function of USP10 in the regulation of ZEB1 protein stability and its ability to mediate tumor metastasis in a preclinical model. Implications: The MEK–ERK-regulated interaction of USP10 with ZEB1 can promote the proteasomal degradation of ZEB1 and thereby suppress its demonstrated ability to mediate tumor metastasis.
Clinical Outcomes and Prognostic Factors in Triple-Negative Invasive Lobular Carcinoma of the Breast
Joshi, Utsav , Gaire, Suman , Yadav, Sumeet Kumar, Adhikari, Anurag , Choong, Grace M. , Couzi, Rima, Leon‐Ferre, Roberto A. , Mutter, Robert W. , Ruddy, Kathryn J. , Haddad, Tufia C. , Yadav, Siddhartha , Choong, Grace, Giridhar, Karthik, Mutter, Robert, Yadav, Siddhartha , Budhathoki, Pravash , Shah, Anish , Giridhar, Karthik V. , Boughey, Judy C. , Hieken, Tina J. , Goetz, Matthew P. , Couch, Fergus J.

Mayo Clinic

No container title available | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2658909/v1 | PMID 36993608 Get It

Abstract Purpose: Triple-negative invasive lobular carcinoma (TN-ILC) of breast cancer is a rare disease and the clinical outcomes and prognostic factors are not well-defined. Methods: Women with stage I-III TN-ILC or triple-negative invasive ductal carcinoma (TN-IDC) of the breast undergoing mastectomy or breast-conserving surgery between 2010 and 2018 in the National Cancer Database were included. Kaplan-Meier curves and multivariate Cox proportional hazard regression were used to compare overall survival (OS) and evaluate prognostic factors. Multivariate logistic regression was performed to analyze the factors associated with pathological response to neoadjuvant chemotherapy. Results: The median age at diagnosis for women with TN-ILC was 67 years compared to 58 years in TN-IDC (p<0.001). There was no significant difference in the OS between TN-ILC and TN-IDC in multivariate analysis (HR 0.96, p=0.44). Black race and higher TNM stage were associated with worse OS, whereas receipt of chemotherapy or radiation was associated with better OS in TN-ILC. Among women with TN-ILC receiving neoadjuvant chemotherapy, the 5-year OS was 77.3% in women with a complete pathological response (pCR) compared to 39.8% in women without any response. The odds of achieving pCR following neoadjuvant chemotherapy were significantly lower in women with TN-ILC compared to TN-IDC (OR 0.53, p<0.001). Conclusion: Women with TN-ILC are older at diagnosis but have similar OS compared to TN-IDC after adjusting for tumor and demographic characteristics. Administration of chemotherapy was associated with improved OS in TN-ILC, but women with TN-ILC were less likely to achieve complete response to neoadjuvant therapy compared to TN-IDC.
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
Raleigh, David R. , Youngblood, Mark W. , Polley, Mei‐Yin C. , Mirchia, Kanish , Won, Minhee , Harmanci, Arif , Vasudevan, Harish N. , Yu, Theresa, Bhave, Varun , Lam, Tai‐Chung , Pu, Jenny Kan-Suen, Chang, Jason Y. , Haberler, Christine , Mawrin, Christian , Rood, Brian , Chew, Jessica, Boreta, Lauren , Butowski, Nicholas , Bush, Nancy Ann Oberheim , Chandler, James P. , Rogers, Leland , Pugh, Stephanie L. , Sneed, Penny K. , Raleigh, David , Choudhury, Abrar , Youngblood, Mark , Leung, Gilberto , Palmer, Joshua D , Berghoff, Anna , Preusser, Matthias , Santagata, Sandro , Solomon, David A , Horbinski, Craig , Perry, Arie , Sahm, Felix , Chen, William C. , Lucas, Calixto‐Hope G. , Maas, Sybren L. N. , Suwala, Abigail Kora , Bayley, James C. , Harmancı, Akdes Serin , Klisch, Tiemo Jürgen , Nguyen, Minh , McCortney, Kathleen , Perlow, Haley K. , Palmer, Joshua D. , Preusser, Matthias , Nicolaides, Theodore , Agnihotri, Sameer , Resnick, Adam , Young, Jacob S. , Braunstein, Steve , Schulte, Jessica D. , Spetzler, David B. , Villanueva-Meyer, Javier E. , Solomon, David A. , Mehta, Minesh P. , Berger, Mitchel S. , Horbinski, Craig , McDermott, Michael , Perry, Arie , Bi, Wenya Linda , Patel, Akash J. , Sahm, Felix , Magill, Stephen T.

Mayo Clinic

No container title available | March 20, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2663611/v1 | PMID 36993741 Get It

Abstract Background Surgery is the mainstay of treatment for meningioma, the most common primary intracranial tumor, but improvements in meningioma risk stratification are needed and current indications for postoperative radiotherapy are controversial. Recent studies have proposed prognostic meningioma classification systems using DNA methylation profiling, copy number variants, DNA sequencing, RNA sequencing, histology, or integrated models based on multiple combined features. Targeted gene expression profiling has generated robust biomarkers integrating multiple molecular features for other cancers, but is understudied for meningiomas. Methods Targeted gene expression profiling was performed on 173 meningiomas and an optimized gene expression biomarker (34 genes) and risk score (0 to 1) was developed to predict clinical outcomes. Clinical and analytical validation was performed on independent meningiomas from 12 institutions across 3 continents (N = 1856), including 103 meningiomas from a prospective clinical trial. Gene expression biomarker performance was compared to 9 other classification systems. Results The gene expression biomarker improved discrimination of postoperative meningioma outcomes compared to all other classification systems tested in the independent clinical validation cohort for local recurrence (5-year area under the curve [AUC] 0.81) and overall survival (5-year AUC 0.80). The increase in area under the curve compared to the current standard of care, World Health Organization 2021 grade, was 0.11 for local recurrence (95% confidence interval [CI] 0.07–0.17, P < 0.001). The gene expression biomarker identified meningiomas benefiting from postoperative radiotherapy (hazard ratio 0.54, 95% CI 0.37–0.78, P = 0.0001) and re-classified up to 52.0% meningiomas compared to conventional clinical criteria, suggesting postoperative management could be refined for 29.8% of patients. Conclusions A targeted gene expression biomarker improves discrimination of meningioma outcomes compared to recent classification systems and predicts postoperative radiotherapy responses.
Real‐time quaking‐induced conversion assays for prions: Applying a sensitive but imperfect test in clinical practice
Jones, Samuel, Lazar, Evelyn, Porter, Amanda , Prusinski, Christian , Brier, Matthew R. , Bucelli, Robert C. , Day, Gregory S. , Jones, Samuel M, Lazar, Evelyn B, Porter, Amanda L, Prusinski, Christian C , Day, Gregory S

Mayo Clinic

European Journal of Neurology | March 20, 2023 | Volume: 30 | Issue: 7 | Pages: 1854-1860

10.1111/ene.15795 | PMID 36940265 Get It

AbstractBackground and purposeReal‐time quaking‐induced conversion (RT‐QuIC) assays offer a sensitive and specific means for detection of prions, although false negative results are recognized in clinical practice. We profile the clinical, laboratory, and pathologic features associated with false negative RT‐QuIC assays and extend these to frame the diagnostic approach to patients with suspected prion disease.MethodsA total of 113 patients with probable or definite prion disease were assessed at Mayo Clinic (Rochester, MN; Jacksonville, FL; Scottsdale, AZ) or Washington University School of Medicine (Saint Louis, MO) from 2013 to 2021. RT‐QuIC testing for prions was performed in cerebrospinal fluid (CSF) at the National Prion Disease Pathology Surveillance Center (Cleveland, OH).ResultsInitial RT‐QuIC testing was negative in 13 of 113 patients (sensitivity = 88.5%). RT‐QuIC negative patients were younger (median = 52.0 years vs. 66.1 years, p < 0.001). Other demographic and presenting features, and CSF cell count, protein, and glucose levels were similar in RT‐QuIC negative and positive patients. Frequency of 14‐3‐3 positivity (4/13 vs. 77/94, p < 0.001) and median CSF total tau levels were lower in RT‐QuIC negative patients (2517 vs. 4001 pg/mL, p = 0.020), and time from symptom onset to first presentation (153 vs. 47 days, p = 0.001) and symptomatic duration (710 vs. 148 days, p = 0.001) were longer.ConclusionsRT‐QuIC is a sensitive yet imperfect measure necessitating incorporation of other test results when evaluating patients with suspected prion disease. Patients with negative RT‐QuIC had lower markers of neuronal damage (CSF total tau and protein 14‐3‐3) and longer symptomatic duration of disease, suggesting that false negative RT‐QuIC testing associates with a more indolent course.
Electronic Health Record Burden Among Gastroenterology Providers Associated With Subspecialty and Training
Bali, Aman S. , Picco, Michael F., Kinnucan, Jami , Kinnucan, Jami A., Bali, Aman , Hashash, Jana G. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | March 20, 2023 | Volume: 118 | Issue: 7 | Pages: 1282-1284

10.14309/ajg.0000000000002254 | PMID 36940436 Get It

INTRODUCTION: Use of the electronic health record (EHR) has become increasingly widespread. Higher EHR burden is associated with burnout, but this has not been specifically investigated among gastroenterology (GI) providers. METHODS: We retrospectively collected measures of EHR use for outpatient GI providers during a 6-month period. We compared metrics across provider sex, subspecialty, and training (physicians vs nonphysician providers [NPPs]). RESULTS: Data collected represented more than 16,000 appointments from 41 providers across the Division of Gastroenterology and Hepatology. Inflammatory bowel disease (IBD) and hepatology specialists spent more time per appointment in the EHR, clinical review, and outside regular hours compared with other subspecialists. NPPs spent more EHR time than physicians. DISCUSSION: IBD and hepatology specialists and NPPs may have disproportionally high EHR burden. More work is needed to understand differences in provider workload to combat burnout.
CS-iCCA, A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma: Establishment and External Validation
Lozada, María E., Zhang, Ning , Yang, Ju Dong , Voss, Molly M., Prasai, Kritika , Amakye, Dominic , Harmsen, William S. , Chaudhary, Sushant , Bathe, Oliver F. , Therneau, Terry M. , Roberts, Lewis R. , Jin, Weidong , Wongjarupong, Nicha , Amakye, Dominic O , Roberts, Lewis R , Jin, Weidong , Yang, Ju Dong , Borad, Mitesh J. , Patel, Tushar , Gores, Gregory J.

Mayo Clinic

American Journal of Gastroenterology | March 20, 2023 | Volume: 118 | Issue: 12 | Pages: 2173-2183

10.14309/ajg.0000000000002258 | PMID 36940423 Get It

INTRODUCTION: Intrahepatic cholangiocarcinoma (iCCA) is a primary liver malignancy with poor prognosis. Current prognostic methods are most accurate for patients with surgically resectable disease. However, a significant proportion of patients with iCCA are not surgical candidates. We aimed to develop a generalizable staging system based on clinical variables to determine prognosis of all patients with iCCA. METHODS: The derivation cohort included 436 patients with iCCA seen between 2000 and 2011. For external validation, 249 patients with iCCA seen from 2000 to 2014 were enrolled. Survival analysis was performed to identify prognostic predictors. All-cause mortality was the primary end point. RESULTS: Eastern Cooperative Oncology Group status, tumor number, tumor size, metastasis, albumin, and carbohydrate antigen 19-9 were incorporated into a 4-stage algorithm. Kaplan-Meier estimates for 1-year survival were 87.1% (95% confidence interval [CI] 76.1–99.7), 72.7% (95% CI 63.4–83.4), 48.0% (95% CI 41.2–56.0), and 16% (95% CI 11–23.5), respectively, for stages I, II, III, and IV. Univariate analysis yielded significant differences in risk of death for stages II (hazard ratio [HR] 1.71; 95% CI 1.0–2.8), III (HR 3.32; 95% CI 2.07–5.31), and IV (HR 7.44; 95% CI 4.61–12.01) compared with stage I (reference). Concordance indices showed the new staging system was superior to the TNM staging for predicting mortality in the derivation cohort, P < 0.0001. In the validation cohort, however, the difference between the 2 staging systems was not significant. DISCUSSION: The proposed independently validated staging system uses nonhistopathologic data to successfully stratify patients into 4 stages. This staging system has better prognostic accuracy compared with the TNM staging and can assist physicians and patients in treatment of iCCA.